2025 Volume 43 Issue 1 Pages 1-9
Synopsis: There is a lack of established evidence regarding of the surgical details and postoperative chemotherapy for high-grade endometrial carcinoma (serous adenocarcinoma, clear cell carcinoma, and mixed carcinoma) Stage IA. At our hospital, the case of high-grade endometrial carcinoma in stage IA was primarily performed simple total hysterectomy, bilateral salpingo-oophorectomy and pelvic lymphadenectomy without adjuvant chemotherapy, we recommend an additional omentectomy and chemotherapy in cases with positive ascitic cytology.Key words: endometrial cancer, special types, peritoneal cytology, prognostic factor
In this study, we examined the treatment outcomes of High-grade endometrial carcinoma in stage IA in our hosupital between 2008 and 2020, and investigated the prognostic and recurrence risk factors, further analyzing by pure and mixed type. The study include 59 cases. The 5-year disease free survival rate was 78.5%, the 5-year overall survival rate was 92.2%. There were 13 cases of recurrence, with peritoneal dissemination being the most common occurring in 9 cases. The positive ascitic cytology was only a recurrence risk factor, which was consistent across different types. These results suggest that in patients with high-grade endometrial cancer with positive ascitic cytology significantly may correlate with recurrence and prognosis, and it may be necessary to considerate adjuvant chemotherapy. If chemotherapy is not selected, more careful follow-up may be important.
